Phaseline

Targets › CHRNB2

CHRNB2 (Neuronal acetylcholine receptor subunit beta-2): drug programs, companies and trials

28 programs from 26 companies in 202 trials: 62 Phase 2, 62 Phase 1, 55 Phase 4, 23 Phase 3; Psychiatry, Other, Oncology; next expected readout Nov 2026.

Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel…. (UniProt, P17787)

Open in Phaseline: the race on CHRNB2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Pennsylvania2-[18F]-FA
Voltage-gated calcium channel modulator
CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STNPhase 4Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis …Nov 2026
University of California, San FranciscoIntravenous TXA
Interleukin-23 inhibitor
ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4Phase 4Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke …Dec 2026
M.D. Anderson Cancer Center[18F]-4FN
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2, CHRNB2, CHRNA4, Tubulin, OPRM1, CD274Phase 4Lymphoma; Tobacco Use Cessation; Cigarette Smoking-Related Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm …Dec 2026
University of California, BerkeleyVarenicline
Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CHRNB2, CHRNA4Phase 4Dry EyeDec 2026
Medical University of South CarolinaVarenicline
Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CHRNB2, CHRNA4Phase 4Nicotine Dependence; Tobacco Use DisorderMar 2027
Ottawa Heart Institute Research CorporationCytisinicline
Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CHRNB2, CHRNA4Phase 4TobaccoApr 2027
Ottawa Heart Institute Research CorporationVarenicline
Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CHRNB2, CHRNA4Phase 4TobaccoApr 2027
University of MiamiNicotine Polacrilex
Neuronal acetylcholine receptor; alpha4/beta2 agonist
CHRNB2, CHRNA4Phase 4Smoking CessationJul 2027
Centre for Addiction and Mental HealthVarenicline
Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CHRNB2, CHRNA4Phase 4Nicotine DependenceJan 2028
M.D. Anderson Cancer CenterVarenicline
Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CHRNB2, CHRNA4Phase 4Tobacco Use Cessation; Cigarette Smoking-Related CarcinomaFeb 2028
University of Wisconsin, MadisonVarenicline
Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CHRNB2, CHRNA4Phase 4Smoking CessationJul 2028
Massachusetts General HospitalVarenicline
Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CHRNB2, CHRNA4Phase 4Nicotine DependenceSep 2028
VA Office of Research and DevelopmentVarenicline
Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CHRNB2, CHRNA4Phase 4VeteransJun 2030
Corporal Michael J. Crescenz VA Medical CenterVarenicline
Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CHRNB2, CHRNA4Phase 4Schizophrenia–
Abramson Cancer Center at Penn MedicineVarenicline
Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CHRNB2, CHRNA4Phase 3HIV/AIDSNov 2026
University of Kansas Medical CenterVarenicline Tartrate
Neuronal acetylcholine receptor; alpha4/beta2 agonist
CHRNB2, CHRNA4Phase 3Smoking ReductionDec 2026
Population Health Research InstituteCytisinicline
Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CHRNB2, CHRNA4Phase 3Smoking (Tobacco) AddictionJan 2027
Sir Mortimer B. Davis - Jewish General HospitalVarenicline
Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CHRNB2, CHRNA4Phase 3Acute Coronary SyndromeMar 2027
Assistance Publique - Hôpitaux de ParisVarenicline
Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CHRNB2, CHRNA4Phase 3Smoking CessationFeb 2029
University of Colorado, DenverVarenicline
Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CHRNB2, CHRNA4Phase 3Human Immunodeficiency Virus–
University of California, Los AngelesCytisinicline
α4β2 nicotinic acetylcholine receptor partial agonist
CHRNA4, CHRNB2Phase 2Smoking CessationDec 2026
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoCytisinicline
Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CHRNB2, CHRNA4Phase 2InflammationDec 2026
Washington State Universityvarenicline
Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CHRNB2, CHRNA4Phase 2Alcohol Use Disorder (AUD)Dec 2026
McNeilNicotine
Neuronal acetylcholine receptor; alpha4/beta2 agonist
CHRNB2, CHRNA4Phase 2Smoking CessationOct 2027
Vikas KotagalVarenicline
Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CHRNB2, CHRNA4Phase 2Parkinson DiseaseJan 2029
University of OklahomaVarenicline
Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CHRNB2, CHRNA4Phase 2Smoking CessationJun 2029
Yale UniversityVarenicline
Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CHRNB2, CHRNA4Phase 2Tobacco Use; E-cigarette UseJun 2029
JT InternationalNicotine
Neuronal acetylcholine receptor; alpha4/beta2 agonist
CHRNB2, CHRNA4Phase 1Smoking Behaviors; Nicotine Dependence; Tobacco Use Disorder; Tobacco …–

Conditions

Smoking Cessation (11) Nicotine Dependence (7) Acute Myeloid Leukemia (6) Smoking (5) Tobacco-Related Carcinoma (4) Tobacco (3) Smoking (Tobacco) Addiction (3) Tobacco Use Disorder (3) Solid Tumor (3) Alcohol Use Disorder (AUD) (2) HIV/AIDS (2) Tobacco Use Cessation (2)

Modalities

small molecule (25), mixed (1), protein or peptide (1)

Companies

Ottawa Heart Institute Research Corporation (2) M.D. Anderson Cancer Center (2) Washington State University (1) Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) University of Wisconsin, Madison (1) University of California, Berkeley (1) Abramson Cancer Center at Penn Medicine (1) Vikas Kotagal (1) University of Kansas Medical Center (1) Assistance Publique - Hôpitaux de Paris (1) Corporal Michael J. Crescenz VA Medical Center (1) Population Health Research Institute (1) University of California, Los Angeles (1) University of California, San Francisco (1) University of Oklahoma (1) Centre for Addiction and Mental Health (1) University of Colorado, Denver (1) JT International (1) Medical University of South Carolina (1) University of Pennsylvania (1)

Related targets

CHRNA4 (28) OPRM1 (3) HTR2A (2) ADRB2 (1) AGTR1 (1) IL12B (1) IL23A (1) PDCD1 (1) NR3C1 (1) MAP2K1 (1) MAP2K2 (1) MS4A1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.